Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Eur J Med Chem. 2012 Jun;52:151-8. doi: 10.1016/j.ejmech.2012.03.012. Epub 2012 Mar 21.
Twenty-eight new 13-n-octylberberine derivatives were synthesized and evaluated for their activities against drug-susceptible Mycobacterium tuberculosis (M. tuberculosis) strain H(37)Rv. Among these compounds, compound 16e was the most effective anti-tubercular agent with a MIC value of 0.125 μg/mL. Importantly, compound 16e exhibited more potent effect against rifampicin (RIF)- and isoniazid (INH)-resistant M. tuberculosis strains than both RIF and INH, suggesting a new mechanism of action. Therefore, it has been selected as a drug candidate for further investigation, or as a chemical probe for identifying protein target and studying tuberculosis biology. We consider 13-n-octylberberine analogs to be a promising novel class of antituberculars against multi-drug-resistant (MDR) strains of M. tuberculosis.
合成了 28 种新型 13-正辛基小檗碱衍生物,并评估了它们对药敏结核分枝杆菌(M. tuberculosis)H(37 )Rv 株的活性。在这些化合物中,化合物 16e 是最有效的抗结核剂,MIC 值为 0.125μg/mL。重要的是,化合物 16e 对利福平(RIF)和异烟肼(INH)耐药结核分枝杆菌菌株的作用比 RIF 和 INH 更强,提示其具有新的作用机制。因此,它已被选为进一步研究的候选药物,或作为鉴定蛋白靶标和研究结核病生物学的化学探针。我们认为 13-正辛基小檗碱类似物是一种有前途的新型抗结核药物,可用于治疗耐多药(MDR)结核分枝杆菌菌株。